Physician profile
Morris Yen
NPI 1679702401
$4,166.53
in general payments reported to CMS, 2019-2025
25 companies · $845 in 2025
The $845 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $451 · 2021: $777 · 2022: $482 · 2023: $519 · 2024: $753 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,117.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $742.46 | 2019-2025 | Dyanavel Xr |
| Pfizer INC. | $542.21 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $448.23 | 2021-2025 | Qelbree, Qelbree |
| Kaleo, INC. | $370.09 | 2019-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $324.83 | 2019-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Corium, LLC | $252.68 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $230.64 | 2020-2021 | |
| Sanofi Pasteur INC. | $199.70 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $184.85 | 2023-2025 | Dupixent |
| Mirum Pharmaceuticals, INC. | $150.07 | 2024 | Livmarli |
| Cranial Technologies, INC | $140.14 | 2019-2024 | Doc Band |
| Sanofi-Aventis U.S. LLC | $80.25 | 2024-2025 | |
| Verrica Pharmaceuticals INC. | $78.70 | 2023-2024 | Ycanth |
| Glaxosmithkline, LLC. | $57.24 | 2020-2022 | |
| Genentech USA, INC. | $55.04 | 2019-2025 | Xolair |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $50.90 | 2019-2023 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $48.28 | 2023-2024 | Flumist Quadrivalent |
| Sobi, INC | $44.84 | 2022-2023 | |
| Seqirus USA INC | $36.17 | 2022-2025 | Flucelvax |
| Adlon Therapeutics L.P. | $26.29 | 2019-2021 | |
| Abbott Laboratories | $23.81 | 2025 | Id Now Instrument |
| Ars Pharmaceuticals Operations, INC. | $23.17 | 2025 | Neffy |
| Abbvie INC. | $20.87 | 2021 | |
| Alk-Abello, INC | $19.32 | 2025 | Neffy |
| Shire North American Group INC | $15.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Yen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.